Obseva Sa (OBSV)

Trade OBSV now with
9/13/2022 1:04:06 AM ObsEva Announces Progress On Restructuring Initiatives; Sees $7.6 Mln Annual Savings
8/22/2022 1:04:51 AM ObsEva Receives Nasdaq Non-Compliance Notice
6/17/2022 1:04:36 AM ObsEva: EC Grants Marketing Authorization For Yselty For Treatment Of Uterine Fibroids
5/17/2022 1:06:11 AM ObsEva Q1 Net Loss $11.8 Mln Or $0.14/Shr Vs Loss $20.0 Mln Or $0.29/Shr Last Year
5/9/2022 1:06:18 AM ObsEva Presents Clinical Data On Oral GnRH Antagonist Linzagolix For Uterine Fibroids At The 2022 ACOG ACSM
5/2/2022 1:04:23 AM ObsEva Appoints Brandi Howard As Chief Clinical Officer, Effective May 9
4/25/2022 1:18:11 AM ObsEva: CHMP Of European Medicines Agency Confirms Positive Opinion For Linzagolix For Uterine Fibroids
3/22/2022 2:05:13 AM ObsEva Announces Addl Efficacy Results From Phase 3 EDELWEISS 3 Trial Of Linzagolix
2/1/2022 1:05:54 AM ObsEva Appoints Katja Buhrer As Chief Strategy Officer, Effective Feb. 1
1/6/2022 1:04:48 AM ObsEva Announces Positive Topline Results From Phase 3 EDELWEISS 3 Trial Of Linzagolix